Ajinomoto CELLiST Korea, a subsidiary of the Ajinomoto Group specializing in cell culture media development and manufacturing, has launched CELLiST™ AAV Production Supplement 1, a newly developed medium supplement designed to significantly enhance viral vector productivity in gene therapy manufacturing.
Breakthrough Developed Through Global Collaboration
The supplement emerged from a strategic collaboration between Ajinomoto Co., Inc. (Tokyo, Japan) and its U.S.-based consolidated subsidiary Forge Biologics, a leading CDMO focused on adeno-associated virus (AAV) development and manufacturing. Demonstration studies confirmed that CELLiST™ AAV Production Supplement 1 increases viral vector productivity by 1.3 to 2 times compared to conventional culture methods. These promising findings were presented at the Japan Society of Gene and Cell Therapy (JSGCT) in July 2025.
Addressing Key Challenges in Gene Therapy Manufacturing
As per the press release, the advancement addresses a key challenge in the rapidly growing gene therapy field. It aims to boost production efficiency while controlling manufacturing costs. With the global gene therapy market projected to grow from USD 7 billion in 2022 to USD 46 billion by 2030, innovative solutions like CELLiST™ AAV Production Supplement 1 are critical to support the rising demand for therapies targeting both common and rare diseases.
Built on Decades of Expertise in Biopharmaceutical Media
For more than 30 years, Ajinomoto CELLiST Korea has led innovation in biopharmaceutical manufacturing by offering high-performance CELLiST™ culture media optimized for CHO and HEK293 cell lines. Ajinomoto Group’s advanced formulation optimization technologies combine with Forge Biologics’ large-scale AAV manufacturing expertise. This new supplement marks a key step in applying AminoScience to enhance gene therapy production.
Supporting Customers Across Asia
Ajinomoto CELLiST Korea plans to leverage CELLiST™ AAV Production Supplement 1 to support customers across Asia. The supplement helps enhance the efficiency and reliability of viral vector manufacturing processes.
Leadership Perspective
“We are excited to introduce CELLiST™ AAV Production Supplement 1 to our customers,” said President Sugiyama of Ajinomoto CELLiST Korea. “Building on the Ajinomoto Group’s strong R&D foundation, our goal is to help gene therapy developers achieve higher productivity, better scalability, and more reliable outcomes in their manufacturing processes.”
Advancing the Future of Biopharmaceutical Manufacturing
Ajinomoto CELLiST Korea remains committed to developing AminoScience-based solutions. These innovations drive progress across the biopharmaceutical landscape, from monoclonal antibodies to next-generation cell and gene therapies.